Whalen Wealth Management Inc. Raises Stake in Lantheus Holdings, Inc. $LNTH

Whalen Wealth Management Inc. raised its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 35.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,872 shares of the medical equipment provider’s stock after buying an additional 1,528 shares during the quarter. Whalen Wealth Management Inc.’s holdings in Lantheus were worth $481,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Signaturefd LLC grew its holdings in Lantheus by 36.5% in the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 116 shares in the last quarter. Quarry LP grew its holdings in Lantheus by 2,350.0% in the 1st quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock valued at $48,000 after buying an additional 470 shares in the last quarter. Hughes Financial Services LLC purchased a new stake in Lantheus in the 1st quarter valued at $81,000. GAMMA Investing LLC grew its holdings in Lantheus by 29.3% in the 1st quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider’s stock valued at $128,000 after buying an additional 298 shares in the last quarter. Finally, AlphaQuest LLC grew its holdings in Lantheus by 252.5% in the 1st quarter. AlphaQuest LLC now owns 1,653 shares of the medical equipment provider’s stock valued at $161,000 after buying an additional 1,184 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Rajiv A. Patel sold 3,365,000 shares of the stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 6,812,000 shares of company stock worth $382,427,380. 2.00% of the stock is owned by corporate insiders.

Lantheus Stock Performance

Shares of Lantheus stock opened at $57.33 on Wednesday. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $118.21. The business’s fifty day simple moving average is $54.23 and its 200-day simple moving average is $71.05. The firm has a market cap of $3.90 billion, a PE ratio of 15.25 and a beta of 0.09. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The firm had revenue of $92.51 million for the quarter. Equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Truist Financial set a $63.00 target price on Lantheus and gave the company a “hold” rating in a report on Monday, August 11th. Weiss Ratings lowered Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday. JMP Securities decreased their price target on Lantheus from $112.00 to $73.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 7th. William Blair reaffirmed a “market perform” rating on shares of Lantheus in a research note on Wednesday, July 16th. Finally, B. Riley decreased their price target on Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research note on Tuesday, September 16th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Lantheus currently has an average rating of “Hold” and an average target price of $74.50.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.